In 2015, 30.3 million Americans—9.4% of the U.S. population—had diabetes mellitus, with type 2 diabetes accounting for 90% to 95% of all cases.1 The prevalence of type 2 diabetes increases with age, though it is extremely high among adults of all ages and has been diagnosed in adolescents as well. In 2012, diabetes-related complications, which include kidney failure, neuropathy, amputations, blindness, and cardiovascular disease, represented an estimated total cost of $245 billion in the United States.1 Diabetes is among the most common medical diagnoses of U.S. adult ED visits and hospitalizations. In 2015 it was the seventh leading cause of death.1
Of the nearly 4 billion prescriptions written in the United States in 2010, an estimated 165 million were for antidiabetic drugs, which ranked sixth among drug classifications prescribed that year.2 As the number of type 2 diabetes diagnoses rises, prescriptions for antidiabetic drugs are expected to increase as well. In order to provide appropriate patient education and ensure safe, effective monitoring of patients receiving pharmacologic treatment for type 2 diabetes, nurses need to understand the mechanisms of action, adverse effects, and special considerations associated with both new as well as older pharmacologic agents. This article describes these agents and current combination therapies. Although a detailed discussion of insulin therapy, which is often required for effective diabetes treatment, is beyond the scope of this article, we note the new insulin combination therapies prescribed to treat type 2 diabetes.
PATHOPHYSIOLOGY OF TYPE 2 DIABETES
Type 2 diabetes is characterized by elevated levels of fasting and postprandial blood glucose as well as glycated hemoglobin (HbA1c). The inability of the body to effectively regulate blood glucose levels results from multiple factors, including genetic predispositions and alterations, environmental and dietary circumstances, and exercise patterns. A common finding in type 2 diabetes is a reduced number of pancreatic beta cells.3 In addition, genetic predisposition may reduce the ability of beta cells to secrete sufficient amounts of insulin in response to high levels of blood glucose. It's estimated that more than 220 genes are associated with the risk of developing type 2 diabetes.4 Research into the genetic alterations that may contribute to type 2 diabetes is relatively new but expanding.
The primary behavioral factors that influence type 2 diabetes development are physical inactivity and a dietary intake that promotes obesity. Diets characterized by high levels of saturated fats have been linked to obesity, beta cell dysfunction, insulin resistance, and glucose intolerance.3
Obesity often causes systemic inflammation, which has been associated with beta cell dysfunction.3 The interaction of these factors produces insulin resistance in the body tissues and impairs the suppression of postprandial glucagon secretion.5
Insulin resistance, which can occur in a variety of tissues, including liver and muscle cells, may result from the inability of insulin to bind to its receptor on the cell or from a post-receptor-binding defect.4 In obesity, insulin resistance develops long before altered glucose regulation is evident.5
According to the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE), lifestyle modification is an essential part of managing type 2 diabetes.6 Lifestyle management should include regular physical activity, nutritional therapy, behavioral support, smoking cessation, and weight control. Several well-conducted randomized controlled trials and large prospective cohort studies have found diet and exercise interventions to be effective in reducing the risk of developing type 2 diabetes.7 Weight control may include pharmacologic or surgical therapy in some cases. Nevertheless, the use of pharmacologic antidiabetic therapy should not be delayed when lifestyle interventions alone are not effective in normalizing blood glucose.
The primary marker used to assess the efficacy of type 2 diabetes management is HbA1c, which may be used to guide pharmacologic therapy. The AACE/ACE recommends an HbA1c level of 6.5% or lower, if it can be safely and affordably maintained. Such factors as the patient's age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia, and motivation and adherence should be considered, with the understanding that management goals may change over time and that higher HbA1c levels may be more appropriate for some patients.6
NONINSULIN PHARMACOLOGIC THERAPY
Biguanides: metformin. The only biguanide approved for use in the United States is metformin. Recommended by the American College of Physicians and the AACE/ACE as first-line pharmacologic treatment for type 2 diabetes when nonpharmacologic therapy does not adequately reduce HbA1c levels, metformin was approved by the U.S. Food and Drug Administration (FDA) in 1995.6, 8 Metformin continues to be used to control blood glucose and to reduce the risk of cardiovascular complications, particularly in overweight and obese patients. In the landmark 1998 UK Prospective Diabetes Study, risk of stroke, myocardial infarction, and mortality were significantly reduced in patients allocated to metformin treatment.9 Metformin, which is not associated with weight gain, has a strong safety profile, few adverse effects, good tolerability, and is the least expensive of the antidiabetic drugs used to treat type 2 diabetes.10-13
Mechanism of action. Metformin works in the liver to inhibit gluconeogenesis and glycogenolysis, which reduces hepatic glucose output.10 It also improves insulin sensitivity in the tissues.14 Because metformin does not stimulate pancreatic secretion of insulin, it is not associated with hypoglycemia, a common adverse effect of other antidiabetic drugs.10
Adverse effects. Metformin has few adverse effects; these may include nausea, anorexia, abdominal cramps, bloating, and diarrhea, all of which are generally mild and transient. The most serious, though rare, adverse effect associated with metformin is lactic acidosis. Risk of metformin-associated lactic acidosis is elevated in patients with renal impairment and with the use of contrast media.10
Special considerations. Metformin is associated with vitamin B12 deficiency, possibly because it may interfere with absorption of vitamin B12 in the distal ileum.10, 15 For this reason, serum vitamin B12 should be monitored in patients with anemia or peripheral diabetic neuropathy. Since the use of iodine-containing contrast agents may cause renal failure in patients treated with metformin, patients scheduled for procedures that involve iodinated contrast media should be advised to suspend metformin usage 48 hours before such procedures and to resume metformin treatment no earlier than 48 hours following the procedures, after renal function is confirmed to have returned to baseline.10
Additional medications. When metformin monotherapy is insufficient, additional agents may be added to achieve glycemic control. Over the past several years, many new classes of drugs, including injectable noninsulin drugs and injectable insulin combinations, have been approved for use in type 2 diabetes. Before selecting any additional medications, the prescriber and patient should discuss costs, insurance coverage, potential benefits, and adverse effects.6, 8
Second-generation sulfonylureas: glimepiride, glipizide, and glyburide. One of the oldest and, after metformin, least expensive categories of noninsulin antidiabetic agents,11 sulfonylureas have been used for the management of type 2 diabetes for more than 50 years. Second-generation sulfonylureas are prescribed as a second-line or adjunctive treatment for type 2 diabetes when patients are unable to achieve target HbA1c goals with metformin monotherapy. The second-generation sulfonylureas are preferred to the first-generation sulfonylureas (chlorpropamide, tolazamide, and tolbutamide) because they are more potent, carry a lower risk of hypoglycemia, and have both a more rapid onset of action and a shorter half-life.16
Mechanism of action. Known as insulin secretagogues, sulfonylureas inhibit the ATP-sensitive potassium channel of the pancreatic beta cells, stimulating pancreatic insulin release and enhancing peripheral insulin sensitivity.17 As pancreatic beta cell function declines with disease progression, sulfonylureas become less effective.11 Since some degree of pancreatic beta cell function is necessary for sulfonylureas to be effective, they are usually prescribed during the early stages of type 2 diabetes.
Adverse effects. Second-generation sulfonylureas are relatively potent in their ability to lower HbA1c levels, but because they work to stimulate endogenous insulin release, they are associated with the greatest risk of hypoglycemia among noninsulin antidiabetic agents.6 Sulfonylureas are also associated with a higher risk of cardiovascular mortality than metformin.18 In addition, second-generation sulfonylureas are associated with such adverse effects as weight gain, gastrointestinal disturbance, and skin rashes.6, 17
Special considerations. All second-generation sulfonylureas are available as generic formulations, contributing to their relatively low cost and wide use. Most of these drugs should be taken with meals once a day or twice daily in divided doses; the exception is glipizide, which should be taken on an empty stomach 30 minutes before a meal.19 Dosages may need to be adjusted in patients with renal insufficiency.19, 20
Meglitinides (glinides): nateglinide and repaglinide. Meglitinides are a selective class of insulin secretagogues that have a more rapid onset but shorter duration of action than the sulfonylureas. The use of meglitinides is limited owing to their frequent dosing.
Mechanism of action. Like sulfonylureas, meglitinides alter the ATP-sensitive potassium channel of the pancreatic beta cells, stimulating pancreatic insulin release. Taken primarily with meals, meglitinides are best suited for managing postprandial glucose elevations or sudden spikes in blood glucose levels.17 Meglitinides are less effective than sulfonylureas in lowering HbA1c levels, but they carry a lower risk of prolonged hypoglycemia.6
Adverse effects. The adverse effects most commonly reported with meglitinide use are hypoglycemia and weight gain.21
Special considerations. Because of their rapid onset, meglitinides should be taken with meals.17 Patients should be advised to monitor blood glucose levels following meals. Meglitinides are primarily metabolized by the cytochrome P-450 enzyme system, and patients taking these drugs should have their liver function monitored.22, 23 Since this drug class is related to the sulfonylureas, patients who do not respond to sulfonylureas typically will not respond to meglitinides.
Thiazolidinediones (glitazones): pioglitazone and rosiglitazone. The thiazolidinediones are effective in reducing HbA1c levels, provide stable glycemic control, and are associated with a low risk of hypoglycemia.6
Mechanism of action. Thiazolidinediones are the only antidiabetic agents that directly increase insulin sensitivity in muscle, fat, and liver tissues.11, 14 The thiazolidinediones are metabolized in the liver.11 Since they do not stimulate insulin secretion, when taken alone they do not cause hypoglycemia.14
Adverse effects. In 2011, the FDA advised against the use of pioglitazone in patients with active bladder cancer or a history of bladder cancer.24 Thiazolidinediones are also associated with elevated risk of bone fracture in women and should not be used by women with osteoporosis or osteopenia.11 Because thiazolidinediones are associated with weight gain and edema, they are contraindicated in patients with New York Heart Association class III or IV heart failure.11, 21
Special considerations. The thiazolidinediones are taken once daily in the morning. Premenopausal female patients using hormonal contraception should be advised that thiazolidinediones may reduce serum levels of ethinyl estradiol and norethindrone, causing ovulation and increasing the risk of pregnancy. All premenopausal women treated with a thiazolidinediones should speak with their contraceptive prescriber about increasing their hormonal contraceptive dosage or using an alternative form of contraception.25, 26
The α-glucosidase inhibitors: acarbose and miglitol. The only α-glucosidase inhibitors approved for use in the United States are acarbose and miglitol. The α-glucosidase inhibitors can be used as monotherapy or in combination with metformin.6
Mechanism of action. The α-glucosidase inhibitors work by impeding the conversion of oligosaccharides to monosaccharides.21 As a result, carbohydrate absorption in the intestine is delayed and blood glucose levels are stabilized.
Adverse effects. The α-glucosidase inhibitors are less effective than metformin and the sulfonylureas in lowering HbA1c levels, but they carry a low risk of hypoglycemia unless used with a sulfonylurea or insulin therapy.21 Adverse effects include bloating, flatulence, and diarrhea.6
Special considerations. The α-glucosidase inhibitors are taken three times a day with meals. Because the drugs work in the intestine, they are contraindicated in patients with any type of bowel disorder.27, 28 In patients taking these drugs, hypoglycemia should be reversed with a glucose, rather than a sucrose, source.11 Creatinine clearance should be monitored.11
Dipeptidyl peptidase 4 (DPP-4) inhibitors: alogliptin, linagliptin, saxagliptin, sitagliptin. The first drug classified as a DPP-4 inhibitor was sitagliptin, which received FDA approval in 2006.29 DPP-4 inhibitors may be used as initial monotherapy when metformin, sulfonylureas, or thiazolidinediones are not well tolerated or are contraindicated.6 DPP-4 inhibitors are also commonly added to metformin in patients who do not meet their treatment goal after three months of metformin monotherapy.
Mechanism of action. These drugs reduce the effects of the enzyme DPP-4, which metabolizes the incretin hormones that are released into the bloodstream from the gastrointestinal system in the presence of food. The incretin hormones are responsible for at least 50% of the insulin secreted following glucose ingestion.30 By inhibiting incretin metabolism, the DPP-4 inhibitors stimulate insulin secretion, thereby reducing blood glucose levels.6
Sitagliptin, the oldest of the DPP-4 inhibitors, has been studied extensively in clinical trials, and has proven effective in reducing HbA1c, fasting plasma glucose, and two-hour postprandial glucose levels when used as monotherapy or in combination with other antidiabetic agents.31 The Comparative Outcomes Study of Metformin Intervention Versus Conventional (COSMIC) Approach demonstrated a continued glucose-lowering effect of combination therapy with sitagliptin and metformin for up to four years in patients with type 2 diabetes.29
Adverse effects. Sitagliptin is associated with constipation, and the prescribing information warns that there have been postmarketing reports of acute pancreatitis associated with the use of all DPP-4 inhibitors. There have been no demonstrated effects of DPP-4 inhibitors on body weight.32-35
Special considerations. DPP-4 inhibitors are taken once daily, with or without meals. Since linagliptin is primarily eliminated in feces, with only about 5% excreted by the kidneys, it may be used instead of other drugs in this class by patients with renal impairment.36
Glucagon-like peptide 1 (GLP-1) receptor agonists: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide. The GLP-1 receptor agonists are administered by subcutaneous injection. The first of these drugs, exenatide, was approved by the FDA in 2005. Although GLP-1 receptor agonists are often used with metformin when treatment goals are not achieved with metformin monotherapy, like the DPP-4 inhibitors they may also be used as initial monotherapy.6 In addition to their glucose-lowering effects, GLP-1 receptor agonists also promote weight loss, though liraglutide is the only drug in this class that is FDA approved for treating obesity.37 The dosing for obesity is higher than that for glycemic control.
Mechanism of action. GLP-1 is an incretin secreted by the intestinal mucosa. By stimulating the GLP-1 receptor, these drugs promote the release of insulin from the pancreas, which lowers blood glucose levels. GLP-1 receptor agonists also suppress glucagon secretion and slow gastric emptying.38
Adverse effects. GLP-1 receptor agonists are associated with nausea, vomiting, constipation, and diarrhea. The risk of hypoglycemia with the use of exenatide is low. There is a risk of injection site reactions for these medications. Clinical trials have reported thyroid neoplasms, elevated calcitonin levels, and goiters in patients treated with liraglutide.39 Nasopharyngitis was reported in an albiglutide efficacy and tolerability study, but the incidence was similar to that in the placebo group.40
Special considerations. Liraglutide may be administered any time of day, independent of meals, but is typically administered in the morning, once daily. Albiglutide, a long-acting agent, is administered once weekly.40 Instruct patients to inject the medication into the thigh, upper arm, or abdomen and to rotate injection sites.
Sodium–glucose cotransporter 2 (SGLT-2) inhibitors: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. The newest of the drugs used to treat type 2 diabetes are the SGLT-2 inhibitors. The first of these drugs received FDA approval in 2013. The SGLT-2 inhibitors are indicated as monotherapy for patients in whom metformin is contraindicated or not tolerated and as combination therapy with metformin or other antidiabetic agents to help patients achieve their goals. These drugs have demonstrated efficacy in significantly reducing HbA1c levels, both as monotherapy and in combination with metformin.41
Mechanism of action. SGLT-2 is responsible for filtering glucose reabsorption in the proximal tubules of the kidney.42 By inhibiting this action, SGLT-2 inhibitors increase urinary excretion of glucose, thereby reducing serum glucose levels.
Adverse effects. When SGLT-2 inhibitors are used in combination with other antidiabetic agents, hypoglycemia may occur. The loss of glucose in the urine may produce osmotic diuresis triggering hypovolemia, postural hypotension, and dizziness. More significant adverse reactions include urinary tract infections, genital mycotic infections (more common in women than men), and an increased risk of amputations, which is particularly associated with canagliflozin and more likely in patients with a history of peripheral vascular disease or prior amputation.42, 43 Canagliflozin is also associated with an increased risk of fracture and should be used cautiously in women.44
Special considerations. The SGLT-2 inhibitors are taken once a day in the morning, with or without food. They are contraindicated in patients with renal disease.
Human amylin analogue: pramlintide. Approved by the FDA in 2005, pramlintide has been shown to improve HbA1c levels by 0.2% to 0.4%.45
Mechanism of action. Amylin is a 37-amino acid peptide that is secreted by pancreatic beta cells in response to the ingestion of starches. It reduces blood glucose levels by slowing gastric emptying, thereby delaying the absorption of carbohydrates, blocking the secretion of glucagon, and enhancing the feeling of fullness, thus limiting the intake of additional carbohydrates. People with type 2 diabetes are often deficient in amylin.46
Adverse effects. Pramlintide is associated with nausea, vomiting, and a diminished appetite.
Special considerations. Pramlintide is injected subcutaneously before meals that contain 250 or more calories or 30 or more grams of carbohydrates.46 This medication should be injected into the thigh or abdomen. The upper arm should not be used for injection owing to the variability of absorption. Pramlintide should not be used in patients with gastroparesis.
An overview of antidiabetic drug classes, their sites and mechanisms of action, and nursing implications are presented in Table 1; associated adverse effects can be found in Table 2.
If patients are not meeting treatment goals with metformin or other monotherapy, additional drugs or combination therapies, some with extended-release formulations, are typically prescribed (see Table 3). Nurses need to familiarize themselves with these combinations to provide effective patient education and continued assessment.
1. Centers for Disease Control and Prevention. National diabetes statistics report, 2017. Estimates of diabetes and its burden in the United States
. Atlanta; 2017. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
3. Kahn SE, et al. Pathophysiology and treatment of type 2 diabetes
: perspectives on the past, present, and future Lancet 2014 383 9922 1068 83
4. Surampudi PN, et al. Emerging concepts in the pathophysiology of type 2 diabetes
mellitus Mt Sinai J Med 2009 76 3 216 26
5. Carrera Boada CA, Martínez-Moreno JM Pathophysiology of diabetes mellitus type 2: beyond the duo “insulin resistance-secretion deficit.” Nutr Hosp 2013 28 Suppl 2 78 87
6. Garber AJ, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes
management algorithm—2018 executive summary Endocr Pract 2018 24 1 91 120
7. Mutie PM, et al. Lifestyle precision medicine: the next generation in type 2 diabetes
prevention? BMC Med 2017 15 1 171
8. Qaseem A, et al. Oral pharmacologic treatment of type 2 diabetes
mellitus: a clinical practice guideline update from the American College of Physicians Ann Intern Med 2017 166 4 279 90
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes
(UKPDS 34) Lancet 1998 352 9131 854 65
10. Apampa B Pharmacology and safe prescribing of metformin NursePrescribing 2012 10 12 597 602
11. George CM, et al. Management of blood glucose with noninsulin therapies in type 2 diabetes
Am Fam Physician 2015 92 1 27 34
12. Inzucchi SE Is it time to change the type 2 diabetes
treatment paradigm? No! Metformin should remain the foundation therapy for type 2 diabetes
Diabetes Care 2017 40 8 1128 32
13. Yandrapalli S, et al. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes
mellitus Postgrad Med 2017 129 8 811 21
14. Johnson T Pharmcology of diabetes drugs
: a perspective for dental hygienists Access: the Newsmagazine of the American Dental Hygienists’ Association 2010 24 6 14 23
15. Wooley AC, Kerr JL Monitoring patients on metformin: recent changes and rationales J Pharm Technol 2018 34 1 28 36
16. Chaudhury A, et al. Clinical review of antidiabetic drugs
: implications for type 2 diabetes
mellitus management Front Endocrinol (Lausanne) 2017 8 6
17. Laight D The pharmacology of oral antidiabetic agents NursePrescribing 2014 12 12 604 7
18. Maruthur NM, et al. Diabetes medications as monotherapy or metformin-based combination therapy
for type 2 diabetes
: a systematic review and meta-analysis Ann Intern Med 2016 164 11 740 51
19. Pfizer. Prescribing information: Glucotrol (glipizide) tablet
. New York, NY; 2008 Sep. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017783s019lbl.pdf
20. Sanofi-Aventis. Prescribing information: Amaryl (glimepiride) tablets
. Bridgewater, NJ; 2013 Oct. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020496s027lbl.pdf
21. Lew KN, Wick A Pharmacotherapy of type 2 diabetes
mellitus: navigating current and new therapies Medsurg Nurs 2015 24 6 413 9
22. Novartis Pharmaceuticals Corporation. Prescribing information: Starlix (nateglinide) tablets
. East Hanover, NJ; 2008 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021204s011lbl.pdf
23. Novo Nordisk A/S. Prescribing information: Prandin (repaglinide) tablets (0.5, 1, and 2 mg)
. Princeton, NJ; 2008 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020741s035lbl.pdf
24. U.S. Food and Drug Administration. Updated FDA review concludes that the use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer
. Silver Spring, MD; 2016 Dec 12. FDA drug safety communication; https://www.fda.gov/Drugs/DrugSafety/ucm519616.htm
25. Takeda Pharmaceuticals Prescribing information: Actos (pioglitazone hydrochloride) tablets for oral use
. Deerfield, IL; 2011 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf
26. Woo TM, Robinsion MV Pharmacotherapeutics for advanced practice nurse prescribers
. 4th ed. Philadelphia: F.A. Davis Company; 2015.
27. Bayer HealthCare Pharmaceuticals. Prescribing information: Precose (acarbose tablets)
. Wayne, NJ; 2011 Nov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020482s025lbl.pdf
28. Pfizer. Prescribing information: Glyset (miglitol) tablets for oral use
. New York, NY; 2012 Aug. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf
29. Ku EJ, et al. Four-year durability of initial combination therapy
with sitagliptin and metformin in patients with type 2 diabetes
in clinical practice; COSMIC study PLoS One 2015 10 6 e0129477
30. Kim W, Egan JM The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 2008 60 4 470 512
31. Plosker GL Sitagliptin: a review of its use in patients with type 2 diabetes
mellitus Drugs 2014 74 2 223 42
32. AstraZeneca Pharmaceuticals Prescribing information: Onglyza (saxagliptin) tablets, for oral use
. Wilmington, DE; 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022350s014lbl.pdf
33. Boehringer Ingelheim Pharmaceuticals. Prescribing information: Tradjenta (linagliptin) tablets
. Ridgefield, CT; 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201280s005lbl.pdf
34. Merck and Company Prescribing information: Januvia (sitagliptin) tablets
. Whitehorse Station, NJ; 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021995s019lbl.pdf
35. Takeda Pharmaceuticals Prescribing information: Nesina (alogliptin) tablets
. Deerfield, IL; 2013 Jan. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf
36. McKeage K Linagliptin: an update of its use in patients with type 2 diabetes
mellitus Drugs 2014 74 16 1927 46
37. Isaacs D, et al. Role of glucagon-like peptide 1 receptor agonists in management of obesity Am J Health Syst Pharm 2016 73 19 1493 507
38. McCormack PL Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes
mellitus Drugs 2014 74 3 325 51
39. Peterson GE, Pollom RD Liraglutide in clinical practice: dosing, safety and efficacy Int J Clin Pract Suppl 2010 167 35 43
40. Davis PN, et al. Albiglutide: a once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes
mellitus Am J Health Syst Pharm 2015 72 13 1097 103
41. Miller EM Elements for success in managing type 2 diabetes
with SGLT-2 inhibitors: overview of the efficacy and safety of SGLT-2 inhibitors in type 2 diabetes
mellitus J Fam Pract 2017 66 2 Suppl S5 S12
42. Dixit D, et al. Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
Am J Health Syst Pharm 2015 72 22 1943 54
43. Filippas-Ntekouan S, et al. SGLT2 inhibitors: are they safe? Postgrad Med 2018 130 1 72 82
44. Wolverton D, Blair MM Fracture risk associated with common medications used in treating type 2 diabetes
mellitus Am J Health Syst Pharm 2017 74 15 1143 51
45. Lee NJ, et al. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus Ann Fam Med 2010 8 6 542 9
46. Edelman S, et al. Pramlintide in the treatment of diabetes mellitus BioDrugs 2008 22 6 375 86